As part of our laboratory drug discovery program aimed at identifying new targeted therapies for the treatment of hematologic malignancies, and, regarding the particular potential of Pim-1 and Pim-2 as targets in leukemia [24,25], we decided to develop new dual Pim-1/Pim-2 specific inhibitors. The gene discussed is PIM2; the disease is leukemia.